Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 128

1.

TRAILshort Protects against CD4 T Cell Death during Acute HIV Infection.

Natesampillai S, Paim AC, Cummins NW, Chandrasekar AP, Bren GD, Lewin SR, Kiem HP, Badley AD.

J Immunol. 2019 Aug 1;203(3):718-724. doi: 10.4049/jimmunol.1900271. Epub 2019 Jun 12.

PMID:
31189571
2.

HIV elite control is associated with reduced TRAILshort expression.

Paim AC, Cummins NW, Natesampillai S, Garcia-Rivera E, Kogan N, Neogi U, Sönnerborg A, Sperk M, Bren GD, Deeks S, Polley E, Badley AD.

AIDS. 2019 Sep 1;33(11):1757-1763. doi: 10.1097/QAD.0000000000002279.

PMID:
31149947
3.

Risks and Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies in Patients with HIV Infection.

Arslan S, Litzow MR, Cummins NW, Rizza SA, Badley AD, Navarro W, Hashmi SK.

Biol Blood Marrow Transplant. 2019 Aug;25(8):e260-e267. doi: 10.1016/j.bbmt.2019.03.021. Epub 2019 Mar 26. Review.

PMID:
30926447
4.

Translation to Practice: Accelerating the Cycle of Innovation to Impact.

Anderson JR, Chung TDY, Clark L, Weis JA, Danielsen AJ, Khosla S, Gores GJ, Badley AD.

Mayo Clin Proc. 2019 Mar;94(3):490-499. doi: 10.1016/j.mayocp.2018.08.008. Epub 2019 Feb 7. Review.

PMID:
30738605
5.

Correction: Both HIV-Infected and Uninfected Cells Express TRAILshort, Which Confers TRAIL Resistance upon Bystander Cells within the Microenvironment.

Nie Z, Aboulnasr F, Natesampillai S, Burke SP, Krogman A, Bren GD, Chung TDY, Anderson JR, Smart MK, Katzmann DJ, Rajagopalan G, Cummins NW, Badley AD.

J Immunol. 2018 Sep 1;201(5):1599. doi: 10.4049/jimmunol.1800867. Epub 2018 Jul 13. No abstract available.

6.

Transient Loss of HIV-1 DNA in an HIV-1 Positive Patient After Kidney Transplantation: A Case Report.

Paim AC, Rizza SA, Badley AD, Prieto M, Taler SJ, Chong PP, Cummins NW.

Am J Med. 2018 Oct;131(10):e423-e424. doi: 10.1016/j.amjmed.2018.04.022. Epub 2018 May 3. No abstract available.

PMID:
29730357
7.

HIV Protease-Generated Casp8p41, When Bound and Inactivated by Bcl2, Is Degraded by the Proteasome.

Natesampillai S, Cummins NW, Nie Z, Sampath R, Baker JV, Henry K, Pinzone M, O'Doherty U, Polley EC, Bren GD, Katzmann DJ, Badley AD.

J Virol. 2018 Jun 13;92(13). pii: e00037-18. doi: 10.1128/JVI.00037-18. Print 2018 Jul 1.

8.

The TRAIL: TRAILshort Axis in HIV Immunopathology.

Aboulnasr F, Paranjape G, Badley AD.

Crit Rev Immunol. 2018;38(6):491-503. doi: 10.1615/CritRevImmunol.2019029632. Review.

PMID:
31002603
9.

Both HIV-Infected and Uninfected Cells Express TRAILshort, Which Confers TRAIL Resistance upon Bystander Cells within the Microenvironment.

Nie Z, Aboulnasr F, Natesampillai S, Burke SP, Krogman A, Bren GD, Chung TDY, Anderson JR, Smart MK, Katzmann DJ, Rajagopalan G, Cummins NW, Badley AD.

J Immunol. 2018 Feb 1;200(3):1110-1123. doi: 10.4049/jimmunol.1701113. Epub 2017 Dec 20. Erratum in: J Immunol. 2018 Sep 1;201(5):1599.

10.

Extensive virologic and immunologic characterization in an HIV-infected individual following allogeneic stem cell transplant and analytic cessation of antiretroviral therapy: A case study.

Cummins NW, Rizza S, Litzow MR, Hua S, Lee GQ, Einkauf K, Chun TW, Rhame F, Baker JV, Busch MP, Chomont N, Dean PG, Fromentin R, Haase AT, Hampton D, Keating SM, Lada SM, Lee TH, Natesampillai S, Richman DD, Schacker TW, Wietgrefe S, Yu XG, Yao JD, Zeuli J, Lichterfeld M, Badley AD.

PLoS Med. 2017 Nov 28;14(11):e1002461. doi: 10.1371/journal.pmed.1002461. eCollection 2017 Nov.

11.

Increasing procaspase 8 expression using repurposed drugs to induce HIV infected cell death in ex vivo patient cells.

Sampath R, Cummins NW, Natesampillai S, Bren GD, Chung TD, Baker J, Henry K, Pagliuzza A, Badley AD.

PLoS One. 2017 Jun 19;12(6):e0179327. doi: 10.1371/journal.pone.0179327. eCollection 2017.

12.

Cardiothoracic Transplant Recipient Mycoplasma hominis: An Uncommon Infection with Probable Donor Transmission.

Sampath R, Patel R, Cunningham SA, Arif S, Daly RC, Badley AD, Wylam ME.

EBioMedicine. 2017 May;19:84-90. doi: 10.1016/j.ebiom.2017.04.026. Epub 2017 Apr 19.

13.

Maintenance of the HIV Reservoir Is Antagonized by Selective BCL2 Inhibition.

Cummins NW, Sainski-Nguyen AM, Natesampillai S, Aboulnasr F, Kaufmann S, Badley AD.

J Virol. 2017 May 12;91(11). pii: e00012-17. doi: 10.1128/JVI.00012-17. Print 2017 Jun 1.

14.

Casp8p41: The Protean Mediator of Death in CD4 T-cells that Replicate HIV.

Sampath R, Cummins NW, Badley AD.

J Cell Death. 2016 Sep 27;9:9-17. eCollection 2016. Review.

15.

Disseminated Mycobacterium chimaera Infection After Cardiothoracic Surgery.

Tan N, Sampath R, Abu Saleh OM, Tweet MS, Jevremovic D, Alniemi S, Wengenack NL, Sampathkumar P, Badley AD.

Open Forum Infect Dis. 2016 Jun 16;3(3):ofw131. eCollection 2016 Sep.

16.

Twenty years of human immunodeficiency virus care at the Mayo Clinic: Past, present and future.

Cummins NW, Badley AD, Kasten MJ, Sampath R, Temesgen Z, Whitaker JA, Wilson JW, Yao JD, Zeuli J, Rizza SA.

World J Virol. 2016 May 12;5(2):63-7. doi: 10.5501/wjv.v5.i2.63. Review.

17.

Prime, Shock, and Kill: Priming CD4 T Cells from HIV Patients with a BCL-2 Antagonist before HIV Reactivation Reduces HIV Reservoir Size.

Cummins NW, Sainski AM, Dai H, Natesampillai S, Pang YP, Bren GD, de Araujo Correia MCM, Sampath R, Rizza SA, O'Brien D, Yao JD, Kaufmann SH, Badley AD.

J Virol. 2016 Mar 28;90(8):4032-4048. doi: 10.1128/JVI.03179-15. Print 2016 Apr.

18.

Casp8p41 and HIV.

Cummins NW, Badley AD.

Oncotarget. 2015 Sep 15;6(27):23042-3. No abstract available.

19.

Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic Analysis.

Cummins NW, Neuhaus J, Chu H, Neaton J, Wyen C, Rockstroh JK, Skiest DJ, Boyd MA, Khoo S, Rotger M, Telenti A, Weinshilboum R, Badley AD; INSIGHT Study Group.

EBioMedicine. 2015 May 12;2(7):706-12. doi: 10.1016/j.ebiom.2015.05.012. eCollection 2015 Jul.

20.

Can HIV Be Cured and Should We Try?

Cummins NW, Badley AD.

Mayo Clin Proc. 2015 Jun;90(6):705-9. doi: 10.1016/j.mayocp.2015.03.008. Epub 2015 May 2. No abstract available.

21.

Casp8p41 generated by HIV protease kills CD4 T cells through direct Bak activation.

Sainski AM, Dai H, Natesampillai S, Pang YP, Bren GD, Cummins NW, Correia C, Meng XW, Tarara JE, Ramirez-Alvarado M, Katzmann DJ, Ochsenbauer C, Kappes JC, Kaufmann SH, Badley AD.

J Cell Biol. 2014 Sep 29;206(7):867-76. doi: 10.1083/jcb.201405051. Epub 2014 Sep 22. Erratum in: J Cell Biol. 2014 Oct 13;207(1):159.

22.

Choice of antiretroviral therapy differentially impacts survival of HIV-infected CD4 T cells.

Cummins NW, Sainski AM, Natesampillai S, Bren GD, Badley AD.

Mol Cell Ther. 2014 Jan 3;2:1. doi: 10.1186/2052-8426-2-1. eCollection 2014.

23.

Making sense of how HIV kills infected CD4 T cells: implications for HIV cure.

Cummins NW, Badley AD.

Mol Cell Ther. 2014 Jul 3;2:20. doi: 10.1186/2052-8426-2-20. eCollection 2014. Review.

24.

"Much ado to achieve nothing: prospects for curing HIV infection".

Badley AD.

Mol Cell Ther. 2014 Mar 26;2:9. doi: 10.1186/2052-8426-2-9. eCollection 2014.

25.

Short communication: CD4 T cell declines occurring during suppressive antiretroviral therapy reflect continued production of Casp8p41.

Cummins NW, Neuhaus J, Sainski AM, Strausbauch MA, Wettstein PJ, Lewin SR, Plana M, Rizza SA, Temesgen Z, Touloumi G, Freiberg M, Neaton J, Badley AD; INSIGHT SMART Study Group.

AIDS Res Hum Retroviruses. 2014 May;30(5):476-9. doi: 10.1089/AID.2013.0243. Epub 2014 Feb 14.

26.

Altering cell death pathways as an approach to cure HIV infection.

Badley AD, Sainski A, Wightman F, Lewin SR.

Cell Death Dis. 2013 Jul 11;4:e718. doi: 10.1038/cddis.2013.248. Review.

27.

Anti-apoptotic mechanisms of HIV: lessons and novel approaches to curing HIV.

Cummins NW, Badley AD.

Cell Mol Life Sci. 2013 Sep;70(18):3355-63. doi: 10.1007/s00018-012-1239-3. Epub 2012 Dec 30. Review.

28.

SDF-1α degrades whereas glycoprotein 120 upregulates Bcl-2 interacting mediator of death extralong isoform: implications for the development of T cell memory.

Trushin SA, Carena AA, Bren GD, Rizza SA, Dong X, Abraham RS, Badley AD.

J Immunol. 2012 Aug 15;189(4):1835-42. doi: 10.4049/jimmunol.1100275. Epub 2012 Jul 16.

29.

Heme oxygenase-1 regulates the immune response to influenza virus infection and vaccination in aged mice.

Cummins NW, Weaver EA, May SM, Croatt AJ, Foreman O, Kennedy RB, Poland GA, Barry MA, Nath KA, Badley AD.

FASEB J. 2012 Jul;26(7):2911-8. doi: 10.1096/fj.11-190017. Epub 2012 Apr 6.

30.

HIV replication, inflammation, and the effect of starting antiretroviral therapy on plasma asymmetric dimethylarginine, a novel marker of endothelial dysfunction.

Baker JV, Neuhaus J, Duprez D, Freiberg M, Bernardino JI, Badley AD, Nixon DE, Lundgren JD, Tracy RP, Neaton JD; INSIGHT SMART Study Group.

J Acquir Immune Defic Syndr. 2012 Jun 1;60(2):128-34. doi: 10.1097/QAI.0b013e318252f99f.

31.

TRAIL dependent fratricidal killing of gp120 primed hepatocytes by HCV core expressing hepatocytes.

Rizza SA, Challagundla KB, Natesampillai S, Bren GD, Sykora J, Walczak H, Badley AD.

PLoS One. 2011;6(11):e27171. doi: 10.1371/journal.pone.0027171. Epub 2011 Nov 14.

32.

Human immunodeficiency virus envelope protein Gp120 induces proliferation but not apoptosis in osteoblasts at physiologic concentrations.

Cummins NW, Klicpera A, Sainski AM, Bren GD, Khosla S, Westendorf JJ, Badley AD.

PLoS One. 2011;6(9):e24876. doi: 10.1371/journal.pone.0024876. Epub 2011 Sep 12.

33.

Isolation of a TRAIL antagonist from the serum of HIV-infected patients.

Schnepple DJ, Shepard B, Bren GD, Cummins NW, Natesampillai S, Trushin S, Algeciras-Schimnich A, Meng XW, Sainski AM, Rizza SA, Kaufmann SH, Badley AD.

J Biol Chem. 2011 Oct 14;286(41):35742-54. doi: 10.1074/jbc.M111.274639. Epub 2011 Aug 22.

34.

The HIV-1-specific protein Casp8p41 induces death of infected cells through Bax/Bak.

Sainski AM, Natesampillai S, Cummins NW, Bren GD, Taylor J, Saenz DT, Poeschla EM, Badley AD.

J Virol. 2011 Aug;85(16):7965-75. doi: 10.1128/JVI.02515-10. Epub 2011 Jun 8.

35.

Patients with discordant responses to antiretroviral therapy have impaired killing of HIV-infected T cells.

Natesampillai S, Nie Z, Cummins NW, Jochmans D, Bren GD, Angel JB, Badley AD.

PLoS Pathog. 2010 Nov 24;6(11):e1001213. doi: 10.1371/journal.ppat.1001213.

36.

CXCR4 Tropic HIV-1 gp120 Inhibition of SDF-1α-Induced Chemotaxis Requires Lck and is Associated with Cofilin Phosphorylation.

Trushin SA, Bren GD, Badley AD.

Open Virol J. 2010 Jun 23;4:157-62. doi: 10.2174/1874357901004010157.

37.
38.

Intracellular Casp8p41 content is inversely associated with CD4 T cell count.

Cummins NW, Jiang W, McGinty J, Bren GD, Bosch RJ, Landay A, Deeks SG, Martin JN, Douek D, Lederman MM, Brenchley J, Badley AD.

J Infect Dis. 2010 Aug 15;202(3):386-91. doi: 10.1086/653705.

39.

Casp8p41 expression in primary T cells induces a proinflammatory response.

Taylor JA, Cummins NW, Bren GD, Rizza SA, Kolbert CP, Behrens MD, Knutson KL, Kahl JC, Asmann YW, Badley AD.

AIDS. 2010 Jun 1;24(9):1251-8. doi: 10.1097/QAD.0b013e3283389e90.

40.

How much gp120 is there?

Cummins NW, Rizza SA, Badley AD.

J Infect Dis. 2010 Apr 15;201(8):1273-4; author reply 1274-5. doi: 10.1086/651434. No abstract available.

PMID:
20225961
41.

Mechanisms of HIV-associated lymphocyte apoptosis: 2010.

Cummins NW, Badley AD.

Cell Death Dis. 2010 Nov 11;1:e99. doi: 10.1038/cddis.2010.77. Review.

42.

CD4 T Cells Treated with gp120 Acquire a CD45R0+/CD45RA+ Phenotype.

Trushin SA, Bren GD, Badley AD.

Open Virol J. 2009 Apr 1;3:21-5. doi: 10.2174/1874357900903010021.

43.

The Biology of TRAIL and the Role of TRAIL-Based Therapeutics in Infectious Diseases.

Shepard BD, Badley AD.

Antiinfect Agents Med Chem. 2009 Apr 1;8(2):87-101.

44.

HIV gp120 induces, NF-kappaB dependent, HIV replication that requires procaspase 8.

Bren GD, Trushin SA, Whitman J, Shepard B, Badley AD.

PLoS One. 2009;4(3):e4875. doi: 10.1371/journal.pone.0004875. Epub 2009 Mar 16.

45.

Nelfinavir/ritonavir reduces acinar injury but not inflammation during mouse caerulein pancreatitis.

Singh VP, Bren GD, Algeciras-Schimnich A, Schnepple D, Navina S, Rizza SA, Dawra RK, Saluja AK, Chari ST, Vege SS, Badley AD.

Am J Physiol Gastrointest Liver Physiol. 2009 May;296(5):G1040-6. doi: 10.1152/ajpgi.90642.2008. Epub 2009 Mar 12.

46.

HIV-1 Tat protein suppresses cholangiocyte toll-like receptor 4 expression and defense against Cryptosporidium parvum.

O'Hara SP, Small AJ, Gajdos GB, Badley AD, Chen XM, Larusso NF.

J Infect Dis. 2009 Apr 15;199(8):1195-204. doi: 10.1086/597387.

47.

HIV induces TRAIL sensitivity in hepatocytes.

Babu CK, Suwansrinon K, Bren GD, Badley AD, Rizza SA.

PLoS One. 2009;4(2):e4623. doi: 10.1371/journal.pone.0004623. Epub 2009 Feb 27.

48.

HIV Protease Cleavage of Procaspase 8 is Necessary for Death of HIV-Infected Cells.

Nie Z, Bren GD, Rizza SA, Badley AD.

Open Virol J. 2008;2:1-7. doi: 10.2174/1874357900802010001.

49.

Analysis of HIV Protease Killing Through Caspase 8 Reveals a Novel Interaction Between Caspase 8 and Mitochondria.

Algeciras-Schimnich A, Belzacq-Casagrande AS, Bren GD, Nie Z, Taylor JA, Rizza SA, Brenner C, Badley AD.

Open Virol J. 2007 Dec 27;1:39-46. doi: 10.2174/1874357900701010039.

50.

Beneficial effect of TRAIL on HIV burden, without detectable immune consequences.

Shepard BD, De Forni D, McNamara DR, Foli A, Rizza SA, Abraham RS, Knutson K, Wettstein PJ, Lori F, Badley AD.

PLoS One. 2008 Aug 28;3(8):e3096. doi: 10.1371/journal.pone.0003096.

Supplemental Content

Loading ...
Support Center